Spexis AG (XSWX:SPEX) Dividend Payout Ratio : 0.00 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Spexis AG Dividend Payout Ratio?

Spexis AG's dividend payout ratio for the months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for Spexis AG's Dividend Payout Ratio or its related term are showing as below:

XSWX:SPEX's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.44
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-06-10), the Dividend Yield % of Spexis AG is 0.00%.

Spexis AG's Dividends per Share for the months ended in Dec. 2023 was CHF0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Spexis AG Dividend Payout Ratio Historical Data

The historical data trend for Spexis AG's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spexis AG Dividend Payout Ratio Chart

Spexis AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividend Payout Ratio

Get a 7-Day Free Trial

Spexis AG Semi-Annual Data
	Dec13	Dec14	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Dividend Payout Ratio	Get a 7-Day Free Trial													-	-	-	-	-

Competitive Comparison of Spexis AG's Dividend Payout Ratio

For the Biotechnology subindustry, Spexis AG's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spexis AG's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spexis AG's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Spexis AG's Dividend Payout Ratio falls into.

Spexis AG Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Spexis AG's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2023 )	/	EPS without NRI (A: Dec. 2023 )
	=	0	/	-0.369
	=	N/A

Spexis AG's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-0.29
	=	N/A

Spexis AG (XSWX:SPEX) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Spexis AG Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Spexis AG's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Spexis AG (XSWX:SPEX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spexis AG (XSWX:SPEX) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

SPEXz:UK

Address

Hegenheimermattweg 125, Allschwil, CHE, CH-4123

Website

https://www.polyphor.com

Spexis AG is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of antibiotics and other specialty pharma products for severe or life-threatening diseases. The company's lead product, murepavadin, is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by World Health Organization. It has one operating segment focusing on the research and development and prospective commercialization of respiratory therapeutics addressing high unmet medical needs.

Spexis AG (XSWX:SPEX) Headlines

No Headlines